Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial have?
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial has 515 citations in the OpenAlex counts ScholarIQ stores.
When was Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial published?
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial has 2018 year in the ScholarIQ index.
What is the open-access status of Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial?
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial has green oa status in the ScholarIQ index.
What is the DOI of Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial?
The DOI for Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial is on the source record.
What is the PMID of Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial?
The PMID for Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial is on the source record.
What is the OpenAlex record for Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial?
The OpenAlex for Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial is on the source record.